Kintara Therapeutics
Company Details
Status: Public
Employees: 11-50
Location:
San Diego, California, United States
Type:
sample
Technology:
sample
sample
About: Our Fight Against Cancer
Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs.
Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies.
A Pipeline of Breakthrough Cancer Therapeutics
VAL-083 is a first-in-class small molecule DNA-targeting agent that exhibits a novel mechanism of action that results in DNA double strand breaks and cancer cell death. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.
VAL-083's indications include:
Glioblastoma Multiforme (GBM)
Ovarian Cancer
Pediatric CNS Tumors
REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds.
REM-001’s indications include:
Cutaneous Metastatic Breast Cancer
Recurrent Basal Cell Carcinoma Nevus Syndrome
Hemodialysis Arteriovenous (AV) Access
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Kintara Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.